Generic Name |
||
---|---|---|
IND |
NVP-AEW541 | |
Brand Name (US) |
||
Manufacturer |
Novartis | |
Drug Type |
Tyrosine Kinase Inhibitor | |
Delivery |
Oral | |
Approval Status |
Phase 1 | |
Indications |
||
Overall Strategy |
GIST cell based | |
Strategy |
Block related tumor signal paths | |
Drug Category |
IGF1R inhibitor |
This is a IGF1R inhibitor in early development. IGF1R is overexpressed in 2/3 of wild-type GISTs and almost all pediatric GISTs.
Patients with wild-type GIST and pediatric GIST may be good candidates for a trial with inhibitors of IGF1R.
Links |
|
|
Targeting Cancer Cells: IGF Receptor-1 Kinase Inhibitors |
Trials of this drug |
|
Trial results |